HAL Allergy Group

HAL Allergy Group is a Netherlands‑based organisation that focuses on the development, manufacture and distribution of allergy‑related products, primarily standardized allergen extracts used for both diagnostic testing and immunotherapy treatment. The company supplies these products to hospitals, clinical laboratories and specialist allergy centres, supporting healthcare providers in identifying specific sensitivities and delivering personalized desensitisation therapies. Its portfolio includes preparations for common environmental allergens such as pollen, dust mites, animal dander and mould, as well as formulations for food allergens where applicable. By concentrating on the production of high‑purity, clinically validated extracts, HAL Allergy Group aims to improve the accuracy of allergy diagnosis and the effectiveness of therapeutic interventions across the regions it serves. The organisation operates within the broader healthcare sector, addressing a growing medical need driven by the increasing prevalence of allergic diseases worldwide.

HAL Allergy Group distinguishes itself through a strong commitment to good manufacturing practice (GMP) compliance and adherence to the stringent quality requirements set by the European Pharmacopoeia and other regulatory frameworks governing allergen products. Its expertise lies in the precise standardisation of allergen potency, a critical factor that ensures consistency and safety in both diagnostic and therapeutic applications. The company also engages in ongoing research and development activities aimed at refining extraction techniques and expanding the range of allergens covered by its product catalogue. In February 2024, HAL Allergy Group experienced a ransomware attack that disrupted its network operations, necessitated the involvement of external cybersecurity experts and raised potential GDPR notification obligations due to possible exposure of personal customer data. This incident highlighted the organisation’s reliance on secure information technology infrastructure while underscoring its responsibility to protect patient and customer information in the context of its healthcare‑focused operations.